Halozyme Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast CancerPRNewsWire • 06/29/20
Halozyme To Participate In The BMO 2020 Prescriptions For Success Healthcare ConferencePRNewsWire • 06/17/20
Halozyme Announces Findings From Janssen's Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® In Light-Chain Amyloidosis Presented At European Hematology Association 25th Annual CongressPRNewsWire • 06/13/20
Why Is Halozyme Therapeutics (HALO) Up 1% Since Last Earnings Report?Zacks Investment Research • 06/10/20
Halozyme Announces Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX® Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple MyelomaPRNewsWire • 06/04/20
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/12/20
Halozyme Therapeutics (HALO) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/11/20
Halozyme Therapeutics (HALO) Down 20.1% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/25/20